Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Aytu Biopharma (AYTU) Other Gross PP&E Adjustments (2016 - 2026)

Aytu Biopharma has reported Other Gross PP&E Adjustments over the past 11 years, most recently at -$1.9 million for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments rose 24.94% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.9 million through Dec 2025, up 24.94% year-over-year, with the annual reading at -$201000.0 for FY2025, 110.11% down from the prior year.
  • Other Gross PP&E Adjustments was -$1.9 million for Q4 2025 at Aytu Biopharma, up from -$2.4 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $2.0 million in Q2 2024 and troughed at -$6.8 million in Q4 2021.
  • The 5-year median for Other Gross PP&E Adjustments is -$965500.0 (2023), against an average of -$1.4 million.
  • Year-over-year, Other Gross PP&E Adjustments tumbled 4573.59% in 2021 and then skyrocketed 4391.18% in 2023.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$6.8 million in 2021, then soared by 95.46% to -$307000.0 in 2022, then crashed by 286.64% to -$1.2 million in 2023, then plummeted by 111.12% to -$2.5 million in 2024, then increased by 24.94% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Gross PP&E Adjustments are -$1.9 million (Q4 2025), -$2.4 million (Q3 2025), and -$201000.0 (Q2 2025).